Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Pfizer’s TUKYSA FDA Approval Opens a New Frontline Breast Cancer Growth Opportunity

Pfizer’s frontline FDA approval for TUKYSA could broaden its oncology opportunity as investors assess the company’s post-COVID pipeline.

Oct 11, 2026
Pharmaceutical

Perrigo Takeover Chatter Puts PRGO Shares on M&A Watch

Reported takeover interest has put Perrigo and its PRGO shares in the spotlight, but no buyer, offer price or deal terms have been disclosed…

Oct 10, 2026
Pharmaceutical

Moderna and Merck Cancer Vaccine Trial Success Puts MRNA and MRK in Focus

Phase 3 melanoma data from Moderna and Merck may strengthen the case for mRNA oncology and add strategic value to Keytruda.

Oct 10, 2026
Pharmaceutical

Teva Hits 52-Week High as FDA Clears First Once-Monthly Schizophrenia Injection

Teva’s WELTRUZA approval gives investors a potential specialty-medicine catalyst as the company advances its branded-pharma strategy.

Oct 10, 2026
Pharmaceutical

XORTX Therapeutics Shares Jump 16.7% as Gout Program Moves Toward IND Filing

XORTX Therapeutics shares traded up 16.7% after news that its gout program is advancing toward an IND submission.

Oct 9, 2026
Pharmaceutical

Bristol Myers Squibb’s Positive Zenbexus Data Put Multiple Myeloma Pipeline in Focus

Bristol Myers Squibb reported positive Phase 3 Zenbexus data, putting its multiple myeloma pipeline and potential regulatory path under inve…

Oct 9, 2026
Pharmaceutical

Teva Shares Rise Premarket After FDA Approves Once-Monthly Schizophrenia Treatment

Teva's ADRs climbed 4.5% premarket after FDA approval, putting its neuroscience pipeline and turnaround execution in focus.

Oct 9, 2026
Pharmaceutical

XORTX Therapeutics Jumps 16.7% as Gout Drug Program Moves Toward IND Filing

XORTX Therapeutics shares rose 16.7% as traders responded to progress toward an IND filing for the company’s accelerated gout drug program.

Oct 9, 2026
Pharmaceutical

FDA Expands Tecentriq Use to Stage III Colon Cancer in Roche Oncology Boost

FDA approval of Tecentriq in stage III colon cancer expands Roche’s oncology opportunity and adds a new competitive angle in checkpoint inhi…

Oct 9, 2026
Pharmaceutical

Teva Shares Rise as FDA Approves Once-Monthly Weltruza Schizophrenia Treatment

Teva shares rose 3.5% to 4.5% premarket after FDA approval of once-monthly Weltruza, sharpening focus on its specialty-medicine pipeline.

Oct 9, 2026
Pharmaceutical

Lipocine’s 30% Surge After Canadian TLANDO Approval Puts Regulatory Catalysts in Focus

Lipocine’s LPCN shares rose 30% after Health Canada approved TLANDO, expanding the drug’s cross-border commercial opportunity.

Oct 8, 2026
Pharmaceutical

Viatris-Pacira $36.50 Cash Deal Puts Merger-Arbitrage Focus on VTRS and PCRX

Viatris’s $36.50-per-share cash agreement to acquire Pacira puts PCRX’s deal spread and VTRS’s balance-sheet flexibility in focus.

Oct 8, 2026